Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

An Exploratory Phase I, Randomized, Observer-blind, Active-controlled, Dose-escalation Trial Evaluating the Safety, Tolerability, and Immunogenicity of an Investigational RNA-based SARS-CoV-2 Vaccine in COVID-19 Vaccine Experienced Healthy Adults

This is an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 given in combination with BNT162b2 Bivalent (original/Omicron BA.4/BA.5) to select a safe and tolerable dose and to evaluate BNT162b4 + BNT162b2 Bivalent (original/Omicron BA.4/BA.5) when given as Dose 2 (booster) in Cohorts 1 and 2 and BNT162b4 + BNT162b2 Monovalent (OMI XBB.1.5) when given as Dose 2 (booster) in Cohorts 3a, 3b, 4a, and 4b. Dose 1 will be given observer-blind and Dose 2 open-label.

The trial will use a staggered dosing process schema, i.e., enrollment into the next higher dose level is done sequentially and subject to safety data from the previous dose levels, with sentinel participants in Cohorts 1, 2, 3a, and 4a. Cohort 3b investigating the same dose level as cohort 3a but in participants aged >55 years will be opened after safety data for participants aged 18-55 years in Cohort 3a has been reviewed. Enrollment into Cohorts 4a and 4b will be opened after safety data for Cohort 3a and 3b has been reviewed.

BNT162b4 plus BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) will be administered co-administered (as a single injection).

In addition, depending upon the observed safety and immunogenicity data, the sponsor may update cohorts to evaluate higher or additional DLs of BNT162b4 in combination with the selected spike-encoding RNA vaccine BNT162b2 Bivalent (original/Omicron BA.4/BA.5) or BNT162b2 Monovalent (OMI XBB.1.5).

Study Overview

• Status: Active, not recruiting
• Conditions: COVID-19; SARS-CoV-2 Infection
• Intervention / Treatment: Biological: BNT162b4 5 µg; Biological: BNT162b4 10 µg; Biological: BNT162b4 15 µg; Biological: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg; Biological: BNT162b4 30 µg; Biological: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg

• Study Type: Interventional
• Enrollment (Estimated): 360
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: BioNTech clinical trials patient information; Phone Number: +49 6131 9084; Email: patients@biontech.de

Study Locations

• United States
  • Arizona
    • Tempe, Arizona, United States, 85281
      • Alliance for Multispecialty Research, LLC
  • California
    • Newport Beach, California, United States, 92663
      • Hoag Hospital
    • San Diego, California, United States, 92123-1881
      • California Research Foundation
    • Walnut Creek, California, United States, 94598
      • Diablo Clinical Research, Inc.
  • Connecticut
    • Milford, Connecticut, United States, 06460
      • Clinical Research Consulting, LLC
  • Florida
    • Hollywood, Florida, United States, 33024
      • Cenexel RCA (Research Centers of America)
    • Miami, Florida, United States, 33173
      • Research Institute of South Florida, Inc.
  • Illinois
    • Chicago, Illinois, United States, 60640
      • Great Lakes Clinical Trials LLC - Andersonville
  • Kansas
    • Lenexa, Kansas, United States, 66219
      • Johnson County Clin-Trials, Inc. (JCCT)
  • Kentucky
    • Lexington, Kentucky, United States, 40536
      • University of Kentucky Center for Clinical and Translational Science (outpatient clinic)
  • Missouri
    • Kansas City, Missouri, United States, 64114
      • Alliance for Multispecialty Research, LLC (Kansas)
  • New York
    • Rochester, New York, United States, 14618
      • Finger Lakes Clinical Research
  • Ohio
    • Cincinnati, Ohio, United States, 45212
      • CTI Clinical Research Center
  • Tennessee
    • Knoxville, Tennessee, United States, 37909
      • Alliance for Multispecialty Research, LLC
  • Texas
    • San Antonio, Texas, United States, 78229
      • Endeavor Clinical Trials, LLC
    • San Antonio, Texas, United States, 78229
      • Clinical Trials of Texas, LLC / Flourish Research
    • Tomball, Texas, United States, 77375
      • DM Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria (all dose groups):

• Have given informed consent by signing and dating the informed consent form (ICF) before initiation of any trial-specific procedures.
• Are willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions, e.g., to follow good practices to reduce their chances of being infected or spreading COVID-19, and other requirements of the trial. This includes that they are able to understand and follow trial-related instructions.
• Are aged 18 years and older at randomization, have a body mass index over 18.5 kg/m^2 and under 35 kg/m^2, and weigh at least 50 kg at Visit 0.

• Are healthy, in the clinical judgment of the investigator based on participant-reported medical history data, and physical examination, 12-lead ECG, vital signs, and clinical laboratory test outcomes at Visit 0.

  • Note: Healthy participants with pre-existing stable disease (e.g., obesity), defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 84 days before Visit 0, can be included.
• Agree not to enroll in another trial with an IMP starting from Visit 0 and until 168 days after receiving the last IMP dose. Inclusion criteria pertaining to Dose 2: If 168 days after the participant's first IMP dose had passed before they consent to Dose 2, they should agree to not enroll in another trial from the time of consent to Dose 2 until 168 days after receiving Dose 2 of the IMP.

• Agree not to be vaccinated with:

  • Non-trial vaccines (except COVID-19 vaccines, as per next sub-bullet) starting 28 days prior to the Dose 1 and until 28 days after receiving of the last IMP dose. Seasonal influenza vaccine is allowed; however, it should be given at least 14 days before or after any administration of IMP. Inclusion criteria pertaining to Dose 2: If 28 days after the participant's first IMP dose had passed before they consent to continue Dose 2, they should not have been vaccinated with non-trial vaccines starting from the time of consent to Dose 2 and until 168 days after receiving the Dose 2 of the IMP.
  • Non-trial COVID-19 vaccines starting at least 90 days prior to the Visit 1 and until completion of the participant's last trial visit.

• Have been vaccinated with at least three doses of an RNA-based COVID-19 vaccine authorized in the United States (US) before Visit 0. The last COVID-19 RNA vaccine dose must have been administered at least 90 days before Visit 1.

  • Note: Documented confirmation of prior COVID-19 vaccine receipt must be obtained prior to randomization.
• Have negative human immunodeficiency virus (HIV) -1 and HIV-2 test results at Visit 0.
• Have negative Hepatitis B surface antigentest results at Visit 0.
• Have negative anti-Hepatitis C virus (HCV) antibodies, or negative HCV polymerase chain reaction test results if the anti-HCV is positive at Visit 0.
• Participants of childbearing potential (POCBP) that have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test result at Visit 0 and negative urine pregnancy test results prior to receiving Dose 1. Participants born female that are postmenopausal or permanently sterilized (verified by medical records) will not be considered POCBP. Inclusion criteria pertaining to Dose 2: POCBP that have a negative urine pregnancy test results prior to receiving Dose 2.
• POCBP who agree to practice a highly effective form of contraception and to require their male sexual partners to use condoms with a spermicidal agent, starting at Visit 0 and continuously until 28 days after receiving the last IMP dose. Inclusion criteria pertaining to Dose 2: If 28 days after the participant's first IMP dose had passed before they consent to continue Dose 2, they should have a negative urine β-HCG pregnancy test result at Visit 7 and agree to practice a highly effective form of contraception and to require their male sexual partners to use condoms with a spermicidal agent, starting from the time they consent to Dose 2 and continuously until 28 days after receiving Dose 2 of IMP.
• POCBP who agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting at Visit 0 and continuously until 28 days after receiving the last IMP dose. Inclusion criteria pertaining to Dose 2: If 28 days after the participant's first IMP dose had passed before they consent to continue Dose 2, they should agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting from the time they consent to Dose 2 and continuously until 28 days after receiving Dose 2 of IMP.
• Men who are sexually active with partners of childbearing potential and who have not had a verified vasectomy (documented in medical records) that agree to use condoms with a spermicidal agent and to practice a highly effective form of contraception with their sexual partners born female starting at Visit 0 and continuously until 28 days after receiving the last IMP dose. Inclusion criteria pertaining to Dose 2: If 28 days after the participant's first IMP dose had passed before they consent to continue Dose 2, they should agree to use condoms with a spermicidal agent and to practice a highly effective form of contraception with their sexual partners born female starting from the time they consent to Dose 2 and continuously until 28 days after receiving Dose 2 of IMP.
• Men who are willing to refrain from sperm donation, starting at Visit 0 and continuously until 28 days after receiving the last IMP dose. Inclusion criteria pertaining to Dose 2: If 28 days after the participant's first IMP dose had passed before they consent to continue Dose 2, they should agree to refrain from sperm donation, starting from the time they consent to Dose 2 and continuously until 28 days after receiving Dose 2 of IMP.

Inclusion Criteria (Dose 2 groups):

Participants are eligible to receive Dose 2 if all of the following criteria (in addition to inclusion criteria above) apply:

• Have given informed consent by signing and dating the ICF reflecting the respective protocol version before administration of Dose 2.
• Have enrolled in a dose cohort and received Dose 1 of BNT162b4 + BNT162b2 Bivalent (original/Omicron BA.4/BA.5) in this trial.
• Are healthy in the opinion of the investigator based on a brief (symptom-directed) physical examination

Exclusion Criteria:

• Breastfeeding or intending to become pregnant starting with Visit 0 until 28 days after receiving the last dose of trial IMP or intending to father children starting with Visit 0 until 28 days after receiving the last trial IMP dose.
• History of any severe adverse reactions to vaccines or to vaccine components and including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded from participation: a participant who had an anaphylactic adverse reaction to pertussis vaccine as a child).

• Current or history of the following medical conditions:

  1. Uncontrolled or moderate or severe respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease); symptoms of asthma severity as defined in the most recent US National Heart, Lung, and Blood Institute asthma management guidelines.
  2. Diabetes mellitus type 1 or type 2, or new onset of Diabetes mellitus type 1 or 2 from the administration of Dose 1, including cases controlled with diet alone (Not excluded: history of isolated gestational diabetes).

  3. Hypertension:

     • If a person has been found to have elevated blood pressure or hypertension during screening or previously, exclude for blood pressure that is not well controlled. Well controlled blood pressure is defined as consistently ≤140 mm Hg systolic and ≤90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be ≤150 mm Hg systolic and ≤90 mm Hg diastolic at Visit 0.
     • If a person does not have a history of elevated blood pressure or hypertension previously or during screening, also exclude for systolic blood pressure ≥150 mm Hg at Visit 0 or diastolic blood pressure ≥100 mm Hg at Visit 0. Exclusion pertaining to Dose 2: Participants who have new onset of worsening hypertension since enrollment, that, in the opinion of the investigator would constitute an increased risk to the individual's participation in Dose 2.
  4. Any current or history of cardiovascular diseases such as myocarditis, pericarditis, myocardial infarction, symptomatic congestive heart failure, cardiomyopathy or clinically significant arrhythmias. Exclusion pertaining to Dose 2: Participants who have new onset of cardiovascular disease since enrollment, that, in the opinion of the investigator would constitute an increased risk to the individual's participation in Dose 2.
  5. A diagnosed bleeding disorder (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions). Exclusion pertaining to Dose 2: Participants who have new onset of a bleeding disorder since enrollment, that, in the opinion of the investigator, would constitute an increased risk to the individual's participation in Dose 2.
  6. Seizure disorders: History of seizure(s) within the past 3 years. Also exclude if participant has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.

  7. Screening 12-lead ECG that is consistent with probable or possible myocarditis or pericarditis, or demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of the trial results. Exclusion pertaining to Dose 2: Only symptomatic participants or whose clinical picture, in the opinion of the investigator, warrant ECG will have a repeat 12-lead ECG prior to Dose 2.

     • Note: ECG changes including but not limited to: paroxysmal or sustained atrial or ventricular arrhythmias, atrioventricular (AV) block (grade 2-3) or bundle branch block, diffuse ST-segment elevation or PR-segment inversion, QTcF interval (QT interval corrected by the Fridericia formula) >450 ms in men and >460 ms in women, changes supporting myocardial infarction and/or myocardial ischemia. Exclusion pertaining to Dose 2: Subjects who have an ECG prior to Dose 2 and have a change or new onset that, in the opinion of the investigator, should not receive Dose 2.
• Current or history of major psychiatric illness, including but not limited to bipolar disorder, major depressive disorder, schizophrenia, autism, and attention deficit-hyperactivity disorder that could interfere with participation and follow-up as required by the trial protocol. Exclusion pertaining to Dose 2: Participants who have a change or new onset psychiatric illness.

• Current or history of the following diseases associated with immune dysregulation:

  • Primary immunodeficiencies.
  • History of solid organ or bone marrow transplantation.
  • Asplenia: any condition resulting in the absence of a functional spleen.
  • Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, or psoriasis. Exclusion pertaining to Dose 2: Participants who have a change or new onset immunodeficiency.
• Received any non-trial IMP within 28 days before Visit 0 or Visit 7.
• Received or planned treatment throughout the entire trial with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent), e.g., for cancer or an autoimmune disease, or planned receipt throughout this trial. Inhaled/nebulized (except high doses as per exclusion criteria above), intraarticular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
• Blood/plasma products and/or immunoglobulin containing therapy (including monoclonal antibodies) received within 120 days before Visit 1 or Visit 7 or administration is planned starting at Visit 0 or prior to Visit 7 until 120 days after the last IMP administration in this trial. Exclusion pertaining to Dose 2: if 28 days after the participant's last IMP dose had passed before they consent to continue Dose 2, blood/plasma products and/or immunoglobulin containing therapy (including monoclonal antibodies) received within 120 days before Dose 2 of IMP (Visit 7) continuously until 120 days after receiving Dose 2 of IMP.
• Received allergy treatment with antigen injections within 28 days before Visit 1 or Visit 7 or where allergy treatment with antigen injections are scheduled within 14 days after any visit with IMP administration in this trial.
• Participants with a history of SARS-CoV-2 infection (symptomatic or asymptomatic) <60 days prior to randomization.
• Have received any non-RNA or unauthorized COVID-19 vaccine, aside from Dose 1 of the current trial.
• Any existing condition which may affect IMP administration and/or assessment of local reactions assessment at the injection site, e.g., tattoos, severe scars, etc.
• Are vulnerable individuals as per International Council for Harmonisation (ICH) E6 definition, i.e., are individuals whose willingness to participate in a clinical trial may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.

• Any screening hematology and/or blood chemistry laboratory value that meets the definition of a Grade ≥1 abnormality at Visit 0, or an abnormal C-reactive protein (identified by any method) or troponin I value.

  • Note: Participants with any stable Grade 1 abnormalities (according to the toxicity grading scale) may be considered eligible at the discretion of the investigator. Gilberts disease, in and of itself, is not considered exclusionary. Exclusion pertaining to Dose 2: Only symptomatic participants or whose clinical picture, in the opinion of the investigator, warrant laboratory investigation, will have a repeat lab(s) prior to Dose 2.
• History of alcohol abuse or drug addiction within 1 year before Visit 0, or a history (within the past 5 years) of substance abuse or known medical, psychological, or social conditions which, in the opinion of the investigator, could compromise their wellbeing if they participate as participants in the trial, or that could prevent, limit, or confound the protocol-specified assessments.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Triple

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BNT162b2 Bivalent 30 µg + BNT162b4 5 µg - participants aged 18-55 years; Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 5 µg. Cohort 1. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1).	Biological: BNT162b4 5 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.; Biological: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Experimental: BNT162b2 Bivalent 30 µg + BNT162b4 10 µg - participants aged 18-55 years; Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 10 µg. Cohort 2. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1)	Biological: BNT162b4 10 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.; Biological: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Experimental: BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 15 µg - participants aged 18-55 years; Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg. Cohort 3a. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1). Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 15 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg	Biological: BNT162b4 15 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.; Biological: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.; Biological: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Experimental: BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 15 µg - participants aged >55 years; Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg. Cohort 3b. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1). Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 15 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 15 µg	Biological: BNT162b4 15 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.; Biological: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.; Biological: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Experimental: BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 30 µg - participants aged 18-55 years; Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg. Cohort 4a. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1). Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 30 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg	Biological: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.; Biological: BNT162b4 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.; Biological: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Experimental: BNT162b2 Bivalent/Monovalent 30 µg + BNT162b4 30 µg - participants aged >55 years; Intramuscular injection. BNT162b2 Bivalent (original/Omicron BA.4/BA.5)/Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg. Cohort 4b. Two doses (At Day 1 and 6 to 7 months post-Dose 1, if the participant consents to a second dose of IMP, otherwise only one dose at Visit V1). Dose 1: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg + BNT162b4 30 µg, Dose 2: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg + BNT162b4 30 µg	Biological: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.; Biological: BNT162b4 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.; Biological: BNT162b2 Monovalent (OMI XBB.1.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Active Comparator: BNT612b2 Bivalent 30 µg - participants aged 18-55 years; Intramuscular injection at Day 1. Cohorts 1, 2 and 3a. BNT612b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg.	Biological: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Active Comparator: BNT612b2 Bivalent 30 µg - participants aged >55 years; Intramuscular injection at Day 1. Cohort 3b. BNT612b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg.	Biological: BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 µg; Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of participants with solicited local reactions at the injection site (pain, erythema/redness, induration/swelling) recorded up to 7 days after every investigational medicinal product (IMP) dose for each DL cohort		Up to 7 days after every IMP dose
Frequency of participants with solicited systemic events (vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills and fever) recorded up to 7 days after every IMP dose for each DL cohort		Up to 7 days after every IMP dose
Frequency of participants with at least one adverse event (AE) occurring up to 28 days after every IMP dose for each DL cohort		Up to 28 days after every IMP dose
Frequency of participants with at least one serious adverse event (SAE) occurring up to 6 months after every IMP dose for each DL cohort		Up to 6 months after every lMP dose
Percentage of dosed participants with abnormal hematology and chemistry laboratory values 3 days (Dose 1 sentinel group only) and 7 days after every IMP dose for each DL cohort		Up to 7 days after every IMP dose
Percentage of dosed participants with grading shifts in hematology and chemistry laboratory assessments between baseline and 3 days (Dose 1 sentinel group only) and 7 days after every IPM dose for each DL cohort		Up to 7 days after every IMP dose
Percentage of dosed participants with new electrocardiogram (ECG) abnormalities 3 days (Dose 1 sentinel group only) and 7 days after every IMP dose for each DL cohort	ECG abnormalities will be included that are consistent with probable or possible myocarditis or pericarditis as defined in the protocol.	Up to 7 days after every IMP dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Geometric mean titers (GMT) at each time point for each DL cohort	SARS-CoV-2 ancestral strain neutralizing titers and SARS-CoV-2 Omicron neutralizing titers (viral strains matching the antigen encoded by BNT162b2).	From Day 1 until Day 180
Percentages of participants with seroresponse at each timepoint after every IMP dose for each DL cohort	SARS-CoV-2 ancestral strain neutralizing titers and SARS-CoV-2 Omicron neutralizing titers (viral strains matching the antigen encoded by BNT162b2).	From Day 1 until Day 180
Geometric mean fold rises (GMFRs) from baseline (pre-Dose 1) to every subsequent timepoint for each DL cohort	SARS-CoV-2 ancestral strain neutralizing titers and SARS-CoV-2 Omicron neutralizing titers (viral strains matching the antigen encoded by BNT162b2).	From Day 1 until Day 180

Collaborators and Investigators

• Sponsor: BioNTech SE
• Collaborators: Pfizer
• Investigators: Study Director: BioNTech Responsible Person, BioNTech SE

Study record dates

Study Major Dates

• Study Start (Actual): November 8, 2022
• Primary Completion (Estimated): October 1, 2024
• Study Completion (Estimated): October 1, 2024

Study Registration Dates

• First Submitted: September 14, 2022
• First Submitted That Met QC Criteria: September 14, 2022
• First Posted (Actual): September 15, 2022

Study Record Updates

• Last Update Posted (Estimated): March 6, 2024
• Last Update Submitted That Met QC Criteria: March 5, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Vaccine; Ribonucleic acid (RNA) vaccine; Active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19
• Other Study ID Numbers: BNT162-21

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No